P glycoprotein and the mechanism of multidrug resistance

Research output: Chapter in Book/Report/Conference proceedingChapter

25 Citations (Scopus)

Abstract

The human P glycoprotein (Pgp; MDR1) is an ATP-driven transporter for hydrophobic drugs and causes multidrug resistance in cancer. Our knowledge related to the mechanistic details of the ATP hydrolytic cycle of MDR1 has recently significantly progressed due to studies on the formation of a catalytic intermediate (occluded nucleotide state). According to the most accepted current model, both catalytic sites in MDR1 are active and ATP is hydrolysed alternatively within the two sites. ATP hydrolysis at one site triggers conformational changes within the protein resulting in drug transport, while hydrolysis of a second ATP molecule (at the other site) is required for resetting the initial ('high-affinity binding') conformation. The two active sites act in a cooperative manner and experiments support a model where the two ATP binding cassette (ABC) domains form a coupled catalytic machinery. Although no high resolution structure is available as yet, some relevant structural information can be deduced from crystal structures obtained for several bacterial ABC units, and the recently solved bacterial ABC-ABC dimer crystal structures may provide the basis for a better understanding of the intramolecular cross-talk between the two catalytic sites. As intramolecular interactions between various domains of Pgp/MDR1 are essential in regulating both the ATPase and transport activity, compounds perturbing these interactions may interfere with the function of the transporter. Such compounds, as well as various substrate analogues may be useful in modulating multidrug resistance in cancer.

Original languageEnglish
Title of host publicationNovartis Foundation Symposium
Pages54-68
Number of pages15
Volume243
Publication statusPublished - 2002

Publication series

NameNovartis Foundation Symposium
Volume243

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Adenosine Triphosphate
Catalytic Domain
Hydrolysis
Pharmaceutical Preparations
Adenosine Triphosphatases
Neoplasms
Nucleotides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Váradi, A., Szakács, G., Bakos, E., & Sarkadi, B. (2002). P glycoprotein and the mechanism of multidrug resistance. In Novartis Foundation Symposium (Vol. 243, pp. 54-68). (Novartis Foundation Symposium; Vol. 243).

P glycoprotein and the mechanism of multidrug resistance. / Váradi, A.; Szakács, G.; Bakos, E.; Sarkadi, B.

Novartis Foundation Symposium. Vol. 243 2002. p. 54-68 (Novartis Foundation Symposium; Vol. 243).

Research output: Chapter in Book/Report/Conference proceedingChapter

Váradi, A, Szakács, G, Bakos, E & Sarkadi, B 2002, P glycoprotein and the mechanism of multidrug resistance. in Novartis Foundation Symposium. vol. 243, Novartis Foundation Symposium, vol. 243, pp. 54-68.
Váradi A, Szakács G, Bakos E, Sarkadi B. P glycoprotein and the mechanism of multidrug resistance. In Novartis Foundation Symposium. Vol. 243. 2002. p. 54-68. (Novartis Foundation Symposium).
Váradi, A. ; Szakács, G. ; Bakos, E. ; Sarkadi, B. / P glycoprotein and the mechanism of multidrug resistance. Novartis Foundation Symposium. Vol. 243 2002. pp. 54-68 (Novartis Foundation Symposium).
@inbook{4419bc39453847efa9959aab38f030e3,
title = "P glycoprotein and the mechanism of multidrug resistance",
abstract = "The human P glycoprotein (Pgp; MDR1) is an ATP-driven transporter for hydrophobic drugs and causes multidrug resistance in cancer. Our knowledge related to the mechanistic details of the ATP hydrolytic cycle of MDR1 has recently significantly progressed due to studies on the formation of a catalytic intermediate (occluded nucleotide state). According to the most accepted current model, both catalytic sites in MDR1 are active and ATP is hydrolysed alternatively within the two sites. ATP hydrolysis at one site triggers conformational changes within the protein resulting in drug transport, while hydrolysis of a second ATP molecule (at the other site) is required for resetting the initial ('high-affinity binding') conformation. The two active sites act in a cooperative manner and experiments support a model where the two ATP binding cassette (ABC) domains form a coupled catalytic machinery. Although no high resolution structure is available as yet, some relevant structural information can be deduced from crystal structures obtained for several bacterial ABC units, and the recently solved bacterial ABC-ABC dimer crystal structures may provide the basis for a better understanding of the intramolecular cross-talk between the two catalytic sites. As intramolecular interactions between various domains of Pgp/MDR1 are essential in regulating both the ATPase and transport activity, compounds perturbing these interactions may interfere with the function of the transporter. Such compounds, as well as various substrate analogues may be useful in modulating multidrug resistance in cancer.",
author = "A. V{\'a}radi and G. Szak{\'a}cs and E. Bakos and B. Sarkadi",
year = "2002",
language = "English",
volume = "243",
series = "Novartis Foundation Symposium",
pages = "54--68",
booktitle = "Novartis Foundation Symposium",

}

TY - CHAP

T1 - P glycoprotein and the mechanism of multidrug resistance

AU - Váradi, A.

AU - Szakács, G.

AU - Bakos, E.

AU - Sarkadi, B.

PY - 2002

Y1 - 2002

N2 - The human P glycoprotein (Pgp; MDR1) is an ATP-driven transporter for hydrophobic drugs and causes multidrug resistance in cancer. Our knowledge related to the mechanistic details of the ATP hydrolytic cycle of MDR1 has recently significantly progressed due to studies on the formation of a catalytic intermediate (occluded nucleotide state). According to the most accepted current model, both catalytic sites in MDR1 are active and ATP is hydrolysed alternatively within the two sites. ATP hydrolysis at one site triggers conformational changes within the protein resulting in drug transport, while hydrolysis of a second ATP molecule (at the other site) is required for resetting the initial ('high-affinity binding') conformation. The two active sites act in a cooperative manner and experiments support a model where the two ATP binding cassette (ABC) domains form a coupled catalytic machinery. Although no high resolution structure is available as yet, some relevant structural information can be deduced from crystal structures obtained for several bacterial ABC units, and the recently solved bacterial ABC-ABC dimer crystal structures may provide the basis for a better understanding of the intramolecular cross-talk between the two catalytic sites. As intramolecular interactions between various domains of Pgp/MDR1 are essential in regulating both the ATPase and transport activity, compounds perturbing these interactions may interfere with the function of the transporter. Such compounds, as well as various substrate analogues may be useful in modulating multidrug resistance in cancer.

AB - The human P glycoprotein (Pgp; MDR1) is an ATP-driven transporter for hydrophobic drugs and causes multidrug resistance in cancer. Our knowledge related to the mechanistic details of the ATP hydrolytic cycle of MDR1 has recently significantly progressed due to studies on the formation of a catalytic intermediate (occluded nucleotide state). According to the most accepted current model, both catalytic sites in MDR1 are active and ATP is hydrolysed alternatively within the two sites. ATP hydrolysis at one site triggers conformational changes within the protein resulting in drug transport, while hydrolysis of a second ATP molecule (at the other site) is required for resetting the initial ('high-affinity binding') conformation. The two active sites act in a cooperative manner and experiments support a model where the two ATP binding cassette (ABC) domains form a coupled catalytic machinery. Although no high resolution structure is available as yet, some relevant structural information can be deduced from crystal structures obtained for several bacterial ABC units, and the recently solved bacterial ABC-ABC dimer crystal structures may provide the basis for a better understanding of the intramolecular cross-talk between the two catalytic sites. As intramolecular interactions between various domains of Pgp/MDR1 are essential in regulating both the ATPase and transport activity, compounds perturbing these interactions may interfere with the function of the transporter. Such compounds, as well as various substrate analogues may be useful in modulating multidrug resistance in cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036361915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036361915&partnerID=8YFLogxK

M3 - Chapter

VL - 243

T3 - Novartis Foundation Symposium

SP - 54

EP - 68

BT - Novartis Foundation Symposium

ER -